Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924)

Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study

(2015) Ronan T. Swords et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors

(2015) J. Sarantopoulos et al.   CLINICAL CANCER RESEARCH

Neddylation pathway is up-regulated in human intrahepatic cholangiocarcinoma and serves as a potential therapeutic target

(2015) Qiang Gao et al.   Oncotarget

Induction of p21-Dependent Senescence by an NAE Inhibitor, MLN4924, as a Mechanism of Growth Suppression

(2015) Lijun Jia et al.   NEOPLASIA

Overactivated Neddylation Pathway as a Therapeutic Target in Lung Cancer

(2014) Lihui Li et al.   JNCI-Journal of the National Cancer Institute

Nedd8-Activating Enzyme Inhibitor MLN4924 Provides Synergy with Mitomycin C through Interactions with ATR, BRCA1/BRCA2, and Chromatin Dynamics Pathways

(2014) K. Garcia et al.   MOLECULAR CANCER THERAPEUTICS

Mutations in UBA3 Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924 in Human Leukemic Cells

(2014) G. Wei Xu et al.   PLoS One

Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer

(2013) S. T. Nawrocki et al.   CLINICAL CANCER RESEARCH

Ubiquitin E3 Ligase CRL4CDT2/DCAF2as a Potential Chemotherapeutic Target for Ovarian Surface Epithelial Cancer

(2013) Wei-Wei Pan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Overcoming Platinum Resistance in Preclinical Models of Ovarian Cancer Using the Neddylation Inhibitor MLN4924

(2013) A. A. Jazaeri et al.   MOLECULAR CANCER THERAPEUTICS

Inactivation of the Cullin (CUL)-RING E3 ligase by the NEDD8-activating enzyme inhibitor MLN4924 triggers protective autophagy in cancer cells

(2012) Zhongguang Luo et al.   Autophagy

Treatment-Emergent Mutations in NAEβ Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924

(2012) Michael A. Milhollen et al.   CANCER CELL

The Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth

(2012) Z. Luo et al.   CANCER RESEARCH

Novel DNA Damage Checkpoints Mediating Cell Death Induced by the NEDD8-Activating Enzyme Inhibitor MLN4924

(2012) J. L. Blank et al.   CANCER RESEARCH

MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy

(2012) Steffan T Nawrocki et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma

(2012) D. W. McMillin et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of NEDD8-conjugation pathway by novel molecules: Potential approaches to anticancer therapy

(2012) Tomoaki Tanaka et al.   Molecular Oncology

WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells

(2012) C Mackintosh et al.   ONCOGENE

The p21-Dependent Radiosensitization of Human Breast Cancer Cells by MLN4924, an Investigational Inhibitor of NEDD8 Activating Enzyme

(2012) Dong Yang et al.   PLoS One

Radiosensitization of Human Pancreatic Cancer Cells by MLN4924, an Investigational NEDD8-Activating Enzyme Inhibitor

(2011) D. Wei et al.   CANCER RESEARCH

Inhibition of NEDD8-Activating Enzyme Induces Rereplication and Apoptosis in Human Tumor Cells Consistent with Deregulating CDT1 Turnover

(2011) M. A. Milhollen et al.   CANCER RESEARCH

Global Identification of Modular Cullin-RING Ligase Substrates

(2011) Michael J. Emanuele et al.   CELL

CRL4Cdt2

(2011) Tarek Abbas et al.   CELL CYCLE

Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma

(2011) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

The NEDD8-Activating Enzyme Inhibitor, MLN4924, Cooperates with TRAIL to Augment Apoptosis through Facilitating c-FLIP Degradation in Head and Neck Cancer Cells

(2011) L. Zhao et al.   MOLECULAR CANCER THERAPEUTICS

Prevention of DNA re-replication in eukaryotic cells

(2011) L. N. Truong et al.   Journal of Molecular Cell Biology

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF- B-dependent lymphoma

(2010) M. A. Milhollen et al.   BLOOD

Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia

(2010) R. T. Swords et al.   BLOOD

NEDD8-Targeting Drug MLN4924 Elicits DNA Rereplication by Stabilizing Cdt1 in S Phase, Triggering Checkpoint Activation, Apoptosis, and Senescence in Cancer Cells

(2010) J. J. Lin et al.   CANCER RESEARCH

Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ

(2010) James E. Brownell et al.   MOLECULAR CELL

Regulation of DNA damage response pathways by the cullin-RING ubiquitin ligases

(2009) Jeffrey Hannah et al.   DNA REPAIR

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

(2009) Teresa A. Soucy et al.   NATURE

Targeting Proteins for Destruction by the Ubiquitin System: Implications for Human Pathobiology

(2008) Alan L. Schwartz et al.   Annual Review of Pharmacology and Toxicology